Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus HYPAQUE M 90.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus HYPAQUE M 90.
HYPAQUE-M,75% vs HYPAQUE-M,90%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Renal: >95% unchanged; biliary/fecal: <5%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent